139 related articles for article (PubMed ID: 9529141)
1. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis.
Vicari AM; Ciceri F; Folli F; Lanzi R; Colombo B; Comi G; Camba L
Leukemia; 1998 Mar; 12(3):441-2. PubMed ID: 9529141
[No Abstract] [Full Text] [Related]
2. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
[No Abstract] [Full Text] [Related]
3. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
[No Abstract] [Full Text] [Related]
4. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
Novoselac AV; Reddy S; Sanmugarajah J
Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
[No Abstract] [Full Text] [Related]
6. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.
Ledda A; Caocci G; Spinicci G; Cocco E; Mamusa E; La Nasa G
Leukemia; 2006 Dec; 20(12):2217-8. PubMed ID: 17051242
[No Abstract] [Full Text] [Related]
7. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Taube F; Stölzel F; Thiede C; Ehninger G; Laniado M; Schaich M
Haematologica; 2011 Jun; 96(6):e31. PubMed ID: 21632839
[No Abstract] [Full Text] [Related]
9. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
Bosca I; Pascual AM; Casanova B; Coret F; Sanz MA
Neurology; 2008 Aug; 71(6):457-8. PubMed ID: 18678830
[No Abstract] [Full Text] [Related]
10. Mitoxantrone-related acute leukemia in two MS patients.
Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
[TBL] [Abstract][Full Text] [Related]
11. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
Hasan SK; Buttari F; Ottone T; Voso MT; Hohaus S; Marasco E; Mantovani V; Garagnani P; Sanz MA; Cicconi L; Bernardi G; Centonze D; Lo-Coco F
Neurology; 2011 Mar; 76(12):1059-65. PubMed ID: 21346221
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukaemia induced by mitoxantrone: case report.
Arruda WO; Montú MB; de Oliveira Mde S; Ramina R
Arq Neuropsiquiatr; 2005 Jun; 63(2A):327-9. PubMed ID: 16100984
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Ellis R; Boggild M
Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.
Ottone T; Hasan SK; Voso MT; Ledda A; Montefusco E; Fenu S; Pagoni M; Hubmann M; Lunghi M; Platzbecker U; Lo-Coco F
Am J Hematol; 2014 Mar; 89(3):346-7. PubMed ID: 24375429
[No Abstract] [Full Text] [Related]
15. Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.
Capobianco M; Malucchi S; Ulisciani S; Fava C; Cambrin GR; Avonto L; Saglio G; Bertolotto A
Neurol Sci; 2008 Jun; 29(3):185-7. PubMed ID: 18612769
[TBL] [Abstract][Full Text] [Related]
16. Mitoxanthrone-induced acute myeloid leukaemia presenting with leukaemia cutis.
Fleming JD; Walsh S; Salisbury J; Du-Vivier AW; Mufti G
Eur J Dermatol; 2013; 23(3):419-20. PubMed ID: 23783563
[No Abstract] [Full Text] [Related]
17. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.
Mogenet I; Simiand-Erdociain E; Canonge JM; Pris J
Ann Pharmacother; 2003 May; 37(5):747-8. PubMed ID: 12708958
[No Abstract] [Full Text] [Related]
18. [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
Nollet S; Berger E; Deconinck E; Baldauf E; Rumbach L
Rev Neurol (Paris); 2006 Feb; 162(2):195-9. PubMed ID: 16518259
[TBL] [Abstract][Full Text] [Related]
19. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.
Sumrall A; Dreiling B
J Miss State Med Assoc; 2007 Jul; 48(7):206-7. PubMed ID: 17939254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
